A retrospective multicenter study to analyze the feasibility and efficacy of sequential systemic treatments in patients with Hepatocellular carcinoma in real life settings
Latest Information Update: 26 May 2020
At a glance
- Drugs Cabozantinib (Primary) ; Durvalumab (Primary) ; Lenvatinib (Primary) ; Nintedanib (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Ramucirumab (Primary) ; Regorafenib (Primary) ; Sorafenib (Primary) ; Tivantinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 26 May 2020 New trial record
- 20 May 2020 Results published in the Alimentary Pharmacology and Therapeutics